Home Cart Sign in  
Chemical Structure| 18550-98-6 Chemical Structure| 18550-98-6

Structure of 3PO
CAS No.: 18550-98-6

Chemical Structure| 18550-98-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

3PO is an inhibitor of PFKFB3. It inhibits the proliferation of various human cancer cells with IC50s ranging from 1.4-24 μmol/L. 3PO can inhibit glucose uptake, reduce intracellular concentrations of Fru-2,6-BP, lactate, ATP, NAD+, and NADH. It can be used in cancer research.

Synonyms: 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 3PO

CAS No. :18550-98-6
Formula : C13H10N2O
M.W : 210.23
SMILES Code : O=C(C1=CC=NC=C1)/C=C/C2=CC=CN=C2
Synonyms :
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
MDL No. :MFCD00224002

Safety of 3PO

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Idiopathic pulmonary fibrosis (IPF) lung myofibroblasts 10 μM 24 hours Inhibition of glycolysis, reversal of the differentiated state of IPF myofibroblasts PMC4731722
Human normal lung fibroblasts MRC-5 10 μM 24 hours Inhibition of glycolysis, reduction of TGF-β1-induced myofibroblast differentiation PMC4731722
Human umbilical vein endothelial cells (HUVECs) 0.20 μM 24 hours To evaluate the effect of R-2-HG on endothelial cell migration, results showed that R-2-HG significantly enhanced the migration ability of HUVECs. PMC7330843
Human liver sinusoidal endothelial cells (LSEC) 15μM Inhibition of glycolysis attenuated stress fiber and focal adhesion formation in LSEC on stiff substrates, and decreased nuclear pore size PMC9391258
Human umbilical vein endothelial cells (HUVECs) 200 µg/ml 24 hours To evaluate the effect of R-2-HG on endothelial cell migration, results showed that R-2-HG significantly enhanced the migration ability of HUVECs. PMC11127458
C2C12 myotubes 10µM 1 hour To investigate the antagonistic effect of Pavulon on nicotinic acetylcholine receptors (nAChR), results showed that Pavulon completely blocked the carbachol-induced Ca2+ response. PMC6859557

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Bleomycin and TGF-β1-induced lung fibrosis models 50 mg/kg Intraperitoneal injection Seven times within 2 weeks Inhibition of glycolysis, attenuation of bleomycin and TGF-β1-induced lung fibrosis PMC4731722
NOD-SCID mice Patient-derived orthotopic GBM xenograft models 25 mg/kg Intraperitoneal injection Three times a week, until mice became moribund or displayed severe neurological symptoms To evaluate the effect of 3PO combined with BEV on tumor vascular normalization, hypoxia alleviation, lactate production reduction, and chemotherapy efficacy. Results showed that dual therapy significantly extended survival, delayed tumor growth, and enhanced the delivery of chemotherapeutic drugs. PMC7330843
Rats Sugen 5416/hypoxia-induced pulmonary hypertension model 50 mg/kg/d intraperitoneal injection Once daily for 5 weeks 3PO almost completely prevented Su/Hx-induced pulmonary hypertension, reduced right ventricular systolic pressure and mean pulmonary arterial pressure, and improved pulmonary artery diastolic function PMC6613097

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.76mL

0.95mL

0.48mL

23.78mL

4.76mL

2.38mL

47.57mL

9.51mL

4.76mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories